Abstract:A new infective outbreak, sustained by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and defined coronavirus disease 2019 (COVID-19), is now spreading all around the world.[1] The clinical course of this respiratory disease is complicated in up to 15% of infected patients by onset of interstitial pneumonia, evolving toward acute respiratory distress syndrome needing mechanical ventilation or admission to the intensive care unit (ICU), and is also often accompanied by multiorgan failure.[2] Since there is now incontrovertible evidence that laboratory hemostasis provides an essential contribution to decision-making and care of the vast majority of human pathologies,[3] we aimed to explore here whether increased D-dimer values—which are a frequent occurrence in patients with COVID-19[4]—may be associated with disease severity.An electronic search was performed in Medline (PubMed interface), Scopus, and Web of Science, using the keywords "laboratory" and "COVID-19" or "coronavirus 2019" or "2019-nCoV" or "SARS-CoV-2," between 2019 and present time (i.e., March 4, 2020), with no language restriction. The title, abstract, and full text of all documents that could be identified based on these search criteria were analyzed, and those reporting information on the difference of D-dimer values between COVID-19 patients with or without severe disease (i.e., those needing mechanical ventilation, ICU admission, or those who died) were finally included in our analysis. The reference list of each identified document was also examined for identifying additional eligible studies. A pooled analysis was finally performed, with calculation of weighted mean difference (WMD) and 95% confidence interval (CI) of D-dimer values between COVID-19 patients with or without severe disease, using MetaXL software Version 5.3 (EpiGear International Pty Ltd., Sunrise Beach, Australia). Mean and standard deviation were extrapolated from sample size, median, and interquartile range (IQR), according to Hozo et al.[5] The study was performed in accordance with the Declaration of Helsinki and with the term of local legislation.Overall, 80 documents could be initially identified based on our search criteria, 77 of which ought to be excluded after title, abstract, or full text reading; since they were review articles (n = 6), commentaries, or other editorial material (n = 1), they did not deal with COVID-19 disease (n = 62), or did not expressly reported the difference of D-dimer values in COVID-19 patients with or without severe disease (n = 8). One additional study could be identified from the reference list of selected articles and another one was published while the article was under revision so that a total number of five studies could finally be included in our analysis.[6] [7] [8] [9] [10] Four of these five studies reported median and IQR values of D-dimer,[6] [7] [8] [9] while the remaining only showed the proportion of patients with D-dimer values above the locally defined diagnostic cut-off.[9] In the first study, Huang et al reported clinical and laboratory data of 41 patients hospitalized with laboratory-confirmed COVID-19[6] and observed that D-dimer values were nearly fivefold higher in those with severe disease (median: 2.4 mg/L; IQR: 0.6–14.4 mg/L) than in those without (median: 0.5 mg/L; IQR: 0.3–0.8 mg/L; p = 0.004). Tang et al also studied 183 patients with COVID-19[7] and found that D-dimer values were nearly 3.5-fold higher in those with severe disease (median: 2.12 mg/L; IQR: 0.77–5.27 mg/L) than in those without (median: 0.61 mg/L; IQR: 0.35–1.29 mg/L; p < 0.001). In the third study, published by Wang et al and including 138 patients hospitalized for COVID-19,[8] D-dimer values were nearly 2.5-fold higher in patients with severe disease (median: 4.14 mg/L; IQR: 1.91–13.2 mg/L) than in those without (median: 1.66 mg/L; IQR: 1.01–2.85 mg/L; p < 0.001). In the third study, Zhou et al studied 191 patients with COVID-19[9] and found that D-dimer values were nearly ninefold higher in patients who died (median: 5.2 mg/L; IQR: 1.5–21.1 mg/L) than in those who survived (median: 0.6 mg/L; IQR: 0.3–1.0 mg/L; p < 0.001). In the study -Abstract Truncated-

Association of serum C-reactive protein (CRP) and D-dimer concentration on the severity of COVID-19 cases with or without diabetes: a systematic review and meta-analysis

Relation of D-dimer levels of COVID-19 patients with diabetes mellitus

D-dimer Level and Diabetes in the COVID-19 Infection

Evaluation of CRP, D-Dimer of clinical significance in Iraqi patients with COVID-19 and associated comorbidities

C-reactive Protein for Predicting Cardiovascular and All-Cause Mortality in Type 2 Diabetic Patients: A Meta-Analysis

D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases

C-reactive protein and clinical outcomes in patients with COVID-19

Elevated D-dimer levels on admission are associated with severity and increased risk of mortality in COVID-19: A systematic review and meta-analysis

D-dimer level in COVID-19 infection: a systematic review

Prevalence and Impact of Diabetes in Patients with COVID-19 in China

C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis

Inflammatory biomarkers predict higher risk of hyperglycemic crises but not outcomes in diabetic patients with COVID-19

The risk factors for mortality of diabetic patients with severe COVID-19: A retrospective study of 167 severe COVID-19 cases in Wuhan

Comorbid Diabetes and the Risk of Disease Severity or Death among 8807 COVID-19 Patients in China: A Meta-Analysis.

Association of Diabetes Mellitus with Disease Severity and Prognosis in COVID-19: A Retrospective Cohort Study

Diabetes Mellitus is Associated with Severe Infection and Mortality in Patients with COVID-19: A Systematic Review and Meta-analysis

Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis

D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis

Meta-Analysis of D-Dimer, hsCRP and Cytokines in COVID-19 Severe/Critical Patients in China